secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2024-02-26T23:59:59+00:00
Accession:  0000950170-24-020123
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics Q4 revenue $1.7M, cash $316M; FT522 first patient dosed, FT825 study initiated
--------------------------------------------------------------------------------

- Cash and investments $316.2M at Dec 31, 2023; Q4 GAAP operating expenses $49.8M (R&D $31.8M, G&A $17.9M).
- Revenue $1.7M from Ono collaboration preclinical activities; no product revenue.
- FT522 (CAR NK) first patient treated; Phase 1 includes ADR technology, regimen with/without chemo conditioning.
- FT825/ONO-8250 (CAR T) Phase 1 started for solid tumors; HER2-targeted with novel synthetic controls.
- CIRM awarded $7.9M grant for FT819 Phase 1 SLE study; study start-up at multiple U.S. sites.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000095017024020123/0000950170-24-020123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000095017024020123/fate-20240226.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-020123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer